Seagen Inc. (SGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

127.55

-5.51

(-4.14%)

At close: 04:00PM EST

128.54

+0.99

(+0.78%)

After hours:

05:58PM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	133.06
Open	132.66
Bid	124.76 x 900
Ask	131.95 x 1300
Day's Range	127.37 - 133.28
52 Week Range	127.37 - 199.00
Volume	1,224,500
Avg. Volume	856,301

Market Cap	23.323B
Beta (5Y Monthly)	0.76
PE Ratio (TTM)	N/A
EPS (TTM)	-1.84
Earnings Date	Feb 09, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	192.67

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

3% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SGEN

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Seagen Inc.
Analyst Report: Seagen Inc.Seagen Inc. (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Rating
Fair Value
Economic Moat
5 days agoMorningstar

All

News

Press Releases

Research Reports

Business Wire
Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
BOTHELL, Wash., January 18, 2022--Seagen Reports Data From SEA-CD40 in Combination with Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma at the ASCO GI Symposium
Business Wire
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
BOTHELL, Wash., January 18, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2021 financial results on Wednesday, February 9, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.
Simply Wall St.
Seagen (NASDAQ:SGEN) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...